bˈoʊθ tˌiːˌɑːɹkˈeɪ bˈiː ænd bˌiːdˌiːˌɛnˈɛf ɑːɹ dˈaʊnɹɪɡjˌʊleɪɾᵻd ɪnðə bɹˈeɪn ʌv ˈɜːli ˌeɪdˈiː pˈeɪʃənts wɪð mˈaɪld kˈɑːɡnᵻtˌɪv ɪmpˈɛɹmənts, wˌaɪl wˈɜːk ɪn mˈaɪs hɐz ʃˈoʊn ðæt ɹᵻdˈuːsɪŋ tˌiːˌɑːɹkˈeɪ bˈiː lˈɛvəlz ɪnðə bɹˈeɪn ʌv ˌeɪdˈiː mˈaʊs mˈɑːdəlz lˈiːdz tʊ ɐ sɪɡnˈɪfɪkənt ˈɪŋkɹiːs ɪn mˈɛmɚɹi dˈɛfɪsˌɪts.
Both TrkB and BDNF are downregulated in the brain of early AD patients with mild cognitive impairments, while work in mice has shown that reducing TrkB levels in the brain of AD mouse models leads to a significant increase in memory deficits.